Business Wire

SoftServe University Celebrates 15th Anniversary

Share

SoftServe, a leading digital authority and consulting company, celebrates the 15th anniversary of SoftServe University, its corporate learning hub. SoftServe University was established in 2006 with the mission to enable SoftServe to achieve its strategic business goals by ensuring a pipeline of exceptional new talent and developing existing associates by providing professional learning solutions. Today, SoftServe University is a fully-fledged corporate education ecosystem that designs and delivers more than 3,000 learning solutions annually to support the company’s now over 12,000 current associates globally.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211116005587/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

SoftServe University Celebrates 15th Anniversary (Graphic: Business Wire)

“SoftServe University is a true differentiator in our industry,” said Galyna Datsiv, VP of Learning and Development at SoftServe. “The ability to learn, gain new competencies, develop the needed skills, and grow within the company makes SoftServe an employer of choice among job seekers.”

SoftServe University helps advance associates’ personal and professional growth in seven learning areas: technology and development, project and program management, business and management, business analysis and product management, personal effectiveness and leadership, language and cross-culture communication, and professional certifications. Its key components include the Talent Acceleration Center (with SoftServe's own IT Academy), Tech School, Business School, Cross-Cultural Communication Center, E-learning Team, and Certification Center. A dedicated Center of Learning Excellence is driving continuous improvement and bringing the best learning management practices, effective tools, global trends, and innovations in cooperation with internal subject matter experts, Learning Partners, and Learning Solutions Architects.

All SoftServe University curriculum is tailored to develop and deliver learning solutions based on company needs, comprehensive job descriptions, and competency models. The learning solutions are available in over 20 different formats, including training, long-term, conventional, and e-learning programs. The company encourages its associates to share their knowledge, skills, and experience through mentoring and coaching initiatives. According to its Annual Report, in 2020 SoftServe University featured over 160 people designing and delivering 3,258 learning solutions worth 244,116 of training hours, with over 10,000 unique learners and an impressive 76 net promoter score (NPS) for its learning solutions.

In recognition of its efforts in creating learning and development opportunities for associates, SoftServe won the Excellence in Practice Award in the ‘Learning and Development’ category in the 2021 Association for Talent Development (ATD) Excellence in Practice Awards. The company has also won Gold in the Best Advance in Coaching and Mentoring nomination at the 2021 Brandon Hall Group Excellence in Leadership Development Awards for its mentoring and coaching practices that help associates grow, gain new competencies, and hone their leadership skills.

SoftServe’s position as the employer of choice has been continuously acknowledged by reputable global and local organizations. Ernst & Young has recognized SoftServe as one of Ukraine’s most attractive employers among Ukrainian students and experienced professionals. The company currently ranks second as an employer brand among Ukraine’s IT companies.

About SoftServe

SoftServe is a digital authority that advises and provides at the cutting-edge of technology. We reveal, transform, accelerate, and optimize the way enterprises and software companies do business. With expertise across healthcare, retail, energy, financial services, software, and more, we implement end-to-end solutions to deliver the innovation, quality, and speed that our clients’ users expect.​​

SoftServe delivers open innovation—from generating compelling new ideas, to developing and implementing transformational products and services. Our work and client experience are built on a foundation of empathetic, human-focused experience design that ensures continuity from concept to release. We empower enterprises and software companies to (re)identify differentiation, accelerate solution development, and vigorously compete in today’s digital economy. No matter where you are in your journey.​ Visit our website, blog, LinkedIn, Facebook, and Twitter pages.​

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Paul Jones
Senior Manager, Analyst and Public Relations
pjone@softserveinc.com

Andrew Kavka
Lead Analyst and Public Relations Specialist
akavk@softserveinc.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye